Table 2.
Clinicopathologic characteristics of patient groups in the study cohort†
| No Recurrence | Recurrence |
|||
|---|---|---|---|---|
| Group 1 (n = 16) | Without progression Group 2 (n = 16) | With progression Group 3 (n = 16) | p value | |
| Gender (%) | 0.025a | |||
| Female | 1 (6) | 7 (44) | 7 (44) | |
| Male | 15 (94) | 9 (56) | 9 (56) | |
| Median age, yr (range) | 66.5 (29–83) | 64.5 (39–76) | 67 (62–86) | 0.38b |
| Tumor grade (%) | 0.47a | |||
| G2 | 14 (88) | 15 (94) | 12 (75) | |
| G3 | 2 (12) | 1 (6) | 4 (25) | |
| Multifocality (%) | 0.11a | |||
| Multifocal | 1 (6) | 0 (0) | 4 (25) | |
| Single tumor | 15 (94) | 16 (100) | 12 (75) | |
| Median follow-up, yr (range) | 7.9 (5.1–12.0) | 8.0 (5.5–12.5) | 5.7 (0.9–10.0) | 0.017b |
| Median no. of recurrences before progression (range) | – | 4 (1–9) | 2.5 (0–7) | 0.035b |
| Median time to first clinically significant event, mo* (95% CI) | – | 11.3 (8.6–43.8) | 7.4 (4.2–12.1) | 0.012c |
| Clinical probability of recurrence§ (%) | – | |||
| Intermediate | 16 (100) | 16 (100) | 16 (100) | |
| Clinical probability of progression§ (%) | 0.051a | |||
| Low | 13 (81) | 15 (94) | 9 (56) | |
| Intermediate to high | 3 (19) | 1 (6) | 7 (44) | |
*
Event is recurrence for group 2, and recurrence or progression (whichever occurred first) for group 3.
§
Based on European Organization for Research and Treatment of Cancer Ta T1 bladder cancer risk tables [4].
a
Fisher exact test.
b
Wilcoxon rank-sum test.
c
Log-rank test.
†
Except for a higher proportion of males in group 1, all groups had comparable demographic and pathologic features.